Immune Pharmaceuticals Inc. (IMNP: OTCQX U.S.) | IMMUNE

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immune Pharmaceuticals Inc. (IMNP: OTCQX U.S.) | IMMUNE APPOINTS CAMERON DURRANT, MD, MBA TO BOARD OF DIRECTORS

Contacts

 

Immune Pharmaceuticals Inc.:

  708 Third Avenue, Suite 210

New York, NY 10017

Anna Baran, Senior Director of Investor Relations and Corporate Communications

Tel: (646) 937-1941

anna.baran@immunepharma.com

 

 

Immune Pharmaceuticals Ltd.:

11C Galgale HaPlada

Herzliya-Pituach, Israel 46733

 

 

Immune Appoints Cameron Durrant, MD, MBA to Board of Directors

 

New York, NY and Herzliya-Pituach, Israel – July 14, 2014  – Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North Premier, Stockholm: IMNP; “Immune” or “the Company”) appointed Dr. Cameron Durrant as new independent director. Dr Durant becomes a Member of the Compensation Committee and the R&D Committee.

 

Dr. Durrant, commented:   'I am excited to join Immune 's board at this critical stage in the evolution of the company. I believe Immune has promising programs in key therapeutic areas with high unmet need, such as immunology and oncology.
Further, I believe that the focus on certain orphan conditions and the prospect of a more
personalized approach underscores the potential for Immune.'

 

Dr. Durrant is an accomplished biotech entrepreneur, marketer, financing, business and corporate development professional with a strong medical base as an MD. He has served as board chairman and director and operated as CEO or interim CEO, as well as CFO, for both private and public companies. Most recently, Dr. Durrant served as a corporate officer of Hi-Tech Pharmacal (recently sold to Akorn) and CEO of the ECR division (subsequently divested by Akorn to Valeant). He has been a senior executive   at Johnson and Johnson as Worldwide Vice President, and previously as Vice President Pharmacia Corporation (until its acquisition by Pfizer). Dr Durrant started his career at Merck and then at GSK . He has served as the founding investor, Chairman, CEO and CFO of publicly-traded PediatRx, Executive Chairman of publicly-traded Anavex, CEO of PediaMed Pharmaceuticals, a founding director of Bexion Pharmaceuticals, a board member of Topaz Pharmaceuticals (acquired by sanofi-aventis),  a board member of Alcyone Life Sciences and ReliefBand Technologies. Dr. Durrant has been an advisor to Microsoft Corporation, Prism Pharmaceuticals (acquired by Baxter), Pilgrim Software (acquired by a private equity group), Aprecia Pharmaceuticals and Saxa Private Equity Partners. He has also been involved in creating companies around targeted early-stage technologies with Cincinnati Children's Hospital and assisted numerous private equity groups in their diligence efforts. Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, and his DipCH from the Melbourne Academy, Australia and his Master of Business Administration from Henley Management College, Oxford, UK.

Dr. Daniel Teper , Immune’s Chairman and CEO, commented : "I have been privileged to work with Cameron in several of his leadership roles at GSK, Pharmacia, J&J and PediaMed. His entrepreneurial drive along with the discipline acquired at leading companies and his extensive board experience at public and private companies will be a strong asset as Immune expands its clinical development and commercialization activities”

 

About Immune Pharmaceuticals Inc.

 

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.  The Company’s lead product candidate, bertilimumab, is in clinical development   for moderate to severe ulcerative colitis and Crohn’s Disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition.   Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from MedImmune, the Global Research and Development arm of Astra-Zeneca.  Immune’s pipeline also includes NanomAbs®, a portfolio of antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, crolibulin, a small molecule in Phase II for (indication) in collaboration with the National Cancer Institute and Amiket™, a Phase III-ready neuropathic pain candidate. Amiket has received Orphan Drug Designation for Post-Herpetic Neuralgia in the US.

 

For more information, please visit Immune’s website at www.immunepharmaceuticals.com , the content of which is not a part of this press release.

 

Erik Penser Bankaktiebolag is engaged as Immune´s Certified Adviser on NASDAQ OMX First North Premier.

 

Forward-Looking Statements

 

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal” or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, a timely basis or at all the risk that we will not obtain approval to market and commercialize any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; risks associated with our ability to protect our intellectual property; risks associate with our ability to raise additional funds; and our liquidity. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.immunepharmaceuticals.com . You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.

###

 

 

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 135

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 112

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 97

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 202

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
Shareholder Alert: Investigation Looms Over GDYN

Updated Category News Views 55

Grid Dynamics Under Legal Scrutiny There’s nothing quite like waking up to find your pick embroiled in an investigation. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) is on the radar, with law firm Levi & Korsinsky diving headfirst into potential infractions of fiduciary duties by some of the company’s top brass. The Lowdown on the Investigation This whole circus was...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 204

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 97

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Gold Tumbles: Kinross Faces Class Action Lawsuit

Updated Category News Views 173

Digging Deep into Kinross's Legal Fallout Well, here's a doozy for those investing in the precious metal market. Kinross Gold Corporation (NYSE: KGC) finds itself knee-deep in legal muck. Investors who bought into the Canadian gold miner's promises might be scrambling, as a class action lawsuit has just been lobbed their way. The culprit? A hefty drop-off in their...

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 97

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading

Top 5 Most Recently Viewed Articles

Pivot Point Consulting Triumphs as KLAS Leader for IT Services

Updated Category News Views 146

Pivot Point Consulting Recognized as a Leader in Managed IT Services For three consecutive years, Pivot Point Consulting has earned the prestigious title of #1 Best in KLAS: Managed IT Services. This recognition, based on outstanding client feedback, highlights their ongoing commitment to excellence in the healthcare IT sector. The Significance of KLAS Rankings KLAS...

Continue Reading
Revolutionizing Intelligent Vision: Leopard Imaging's New Offerings

Updated Category News Views 203

Revolutionizing Intelligent Vision Solutions Leopard Imaging Inc., a pioneering company in intelligent vision technology, has unveiled its groundbreaking high-resolution RGB-IR stereo camera series, known as Eagle. This series is powered by two of the most advanced technologies from NVIDIA: Holoscan and Jetson Thor. As a leading innovator in the realm of intelligent...

Continue Reading
Gartner's CEO Eugene Hall Executes Major Stock Sales

Updated Category News Views 320

Eugene Hall's Major Stock Sales at Gartner Gartner Inc. (NYSE: IT) is in the spotlight following a significant stock sale by its Chairman and CEO, Eugene A. Hall. This recent move, detailed in an SEC filing, shows that Hall sold shares worth a considerable total of $17,213,808. Overview of Hall's Stock Transactions Hall's stock sales occurred over several transactions,...

Continue Reading
How Canadian Tariffs Could Impact These 5 Companies

Updated Category News Views 1409

Understanding the Potential Impact of Canadian Tariffs The announcement of possible tariffs on Canadian imports has taken many businesses by surprise, igniting a wave of concern across multiple sectors. Companies are now racing to reassess their strategies as new cost structures could potentially shape their futures. What Does This Mean for U.S. Companies? The initiative...

Continue Reading
Holley Performance Brands Launches Major Stock Offering

Updated Category News Views 309

Holley Performance Brands Unveils Secondary Stock Offering Holley Performance Brands (NYSE: HLLY) has recently made headlines by announcing a secondary offering of its common stock, which aims to raise capital and create further investment opportunities for investors. This move underscores Holley's commitment to enhancing its presence in the automotive performance market....

Continue Reading